News | Prostate Cancer | June 17, 2016

Illinois Hospital Offering C-11 Choline PET Imaging for Prostate Cancer

Studies show imaging with radiotracer increases detection rates by 32 percent

June 17, 2016 — Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline positron emission tomography (PET)/computed tomography (CT) and PET/magnetic resonance imaging (MRI) to patients who have biochemical relapse of prostate cancer. This comes after completing a two-year clinical trial to detect prostate cancer in earlier stages.

C-11 choline PET/CT uses a U.S. Food and Drug Administration (FDA)-approved tracer which, after injection, highlights the precise location of prostate cancer with much greater precision and sensitivity than traditional scans.

Decatur Memorial Hospital is one of a very few hospitals in the United States able to provide this imaging procedure.

“The adoption of a C-11 choline PET/CT imaging program puts the DMH Cancer Care Institute at the forefront of advancements in detection and treatment of prostate cancer,” said Decatur Memorial Hospital President & CEO Timothy D. Stone Jr. “This technology gives us an extremely unique tool to potentially save more lives through earlier detection and more effective treatment.”

Prostate cancer affects one in six men in America. In 2016, approximately 180,000 men will be diagnosed with prostate cancer, and approximately 26,000 men will die from the disease annually. According to published reports, most men who die of prostate cancer do so after either primary local or systemic therapy has failed.

Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy. Conventional imaging tools such as CT scan, bone scan or MRI might show the precise location of prostate cancer only once PSA has reached a value of 20.0 ng/mL – 30.0 ng/mL. The optimum PSA value for lesion detection was determined to be between 1.7 and 2.0 ng/mL to obtain a maximal clinical benefit for detection of prostate cancer in men who have a biochemical relapse after primary treatment. This earlier and more precise detection can allow treatment to begin sooner and to be more accurately targeted.

Following the injection of C-11 choline, prostate cancer cells absorb the choline and the scanner picks up the exact locations of tracer concentrations. Lesions appear as brightly illuminated spots or areas on the scan. C-11 choline has a rapid rate of decay, losing half of its radioactivity every 20 minutes, which means the tiny amount of original radioactivity is gone quickly from the patient’s body.

In the largest published study in the U.S. on C-11 choline imaging, there was a 32 percent increased detection rate of prostate cancer lesions which were not identified on conventional CT scan and bone scan.

DMH Cancer Care Institute recently concluded a two-year clinical research trial for recurrent prostate cancer. The trial was designed to measure the performance characteristics of C11-choline PET/CT and PET/MRI in the detection of metastatic prostate cancer in patients with a relapse of cancer after primary treatment.

Nearly 110 men between the ages of 51 and 86 underwent a C11-choline PET/CT and MRI scan at Decatur Memorial Hospital as part of this trial and were evaluated for evidence of metastatic prostate cancer. Results of the study are still in progress but assessment to date is consistent with reports from Europe and the Mayo Clinic.

“C-11 choline is changing the way we detect and treat prostate cancer. It allows us to pinpoint the exact location of cancer in the body,” said urologic oncologist Thomas H. Tarter, M.D., Ph.D. “This level of accuracy at the very early stages of cancer allows for faster, more effective treatment that can increase survival rates. It’s applied technology that touches patients.”

C-11 choline is produced on-site at Decatur Memorial Hospital with a cyclotron, developed by GE. Decatur Memorial Hospital was the first non-commercial, non-academic GE PETtrace site to develop and implement on-site use of a cyclotron to produce nuclear isotopes in the performance of various diagnostic imaging tests and day-to-day clinical operation of patient care.

For more information: www.dmhcares.com

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System
News | Focused Ultrasound Therapy | March 19, 2019
EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm...